Key Laboratory of Carcinogenesis and Intervention of Jiangsu Province, China Pharmaceutical University, Nanjing 210009, China.
Eur J Med Chem. 2011 Sep;46(9):3942-52. doi: 10.1016/j.ejmech.2011.05.066. Epub 2011 Jun 25.
IκB kinase β (IKKβ) is an important anti-cancer target that plays crucial role in activating the transcription factor NF-κB in response to various inflammatory stimuli. In order to discover novel IKKβ inhibitors, a 3D chemical-feature-based QSAR pharmacophore model was established. A homology model of IKKβ enzyme was also developed to study the binding mode of IKKβ and its inhibitors. The two models were consistent in predicting the binding conformation of IKKβ inhibitor. Based on the virtual screening using the pharmacophore model, 16 compounds from SPECS database were selected after multiple filtrations for biological test. Two compounds with IC(50) values lower than 10 μM were discovered.
IKKβ 是一种重要的抗癌靶点,在各种炎症刺激下,它在激活转录因子 NF-κB 中起着关键作用。为了发现新型 IKKβ 抑制剂,建立了基于 3D 化学特征的 QSAR 药效团模型。还开发了 IKKβ 酶的同源模型,以研究 IKKβ 及其抑制剂的结合模式。这两个模型在预测 IKKβ 抑制剂的结合构象方面是一致的。基于药效团模型的虚拟筛选,从 SPECS 数据库中选择了 16 种化合物,经过多次过滤后进行了生物测试。发现了两种 IC50 值低于 10 μM 的化合物。